Charles Kuzma, M.D.
Hematology & Oncology Physician in Pinehurst, North Carolina. This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,215 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Charles Kuzma, M.D. reported a CMS MIPS final score of 88.3/100 - above the 83.1 national average - and filed 1,178 Medicare Part D claims in 2023.
- 88.3/100
- MIPS score · +5 vs avg
- 1K
- Part D claims, 2023
- 74%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Charles Kuzma, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
88 Top 44% higher than 56% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Charles Kuzma, M.D. sits
This provider among hematology & oncology physician peers
Across the 4,233 hematology & oncology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Charles Kuzma, M.D. writes more Part D claims than 69% of them and scores higher on MIPS quality than 55% - placing this provider in the high-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one hematology & oncology physician peer from a representative sample of 60; the gold marker is Charles Kuzma, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
Charles Kuzma, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Charles Kuzma, M.D.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in North Carolina
How Hematology & Oncology Physician compares to other specialties among North Carolina providers
Largest specialties in North Carolina (% of in-state providers)
Hematology & Oncology Physician ranks #67 among North Carolina's specialties (0.2% of in-state providers)
Each bar is a specialty's share of the North Carolina provider total, by primary NUCC taxonomy. The highlighted bar is Hematology & Oncology Physician; the long tail of smaller specialties is omitted for legibility.
Medicare quality performance, MIPS
Charles Kuzma, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 88.3/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Hematology & Oncology Physician) - 88.3/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Hematology & Oncology Physician US NPIs
88.3/100 MIPS final score - 5.2 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Hematology & Oncology Physician. Quality dim: 75.8. Cost dim: 86.8.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Charles Kuzma, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 220 PAGE RD, Pinehurst, NC, 28374, with a listed phone of (910) 715-3500. NPI 1063469856 was issued on 05/28/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what Kuzma most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 1,178 prescription claims written by this provider, covering 220 Medicare beneficiaries and totaling roughly $5.1 million in drug spend, split 26% brand-name and 74% generic by claim count, with an opioid prescribing rate of 3.1%. These figures capture only Medicare Part D, commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 88.3/100 for the 2023 performance year (Quality 75.8, Cost 86.8), compared with the national average of 83.1.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1063469856 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 05/28/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm Charles Kuzma, M.D.'s current license status, disciplinary history, and board certifications with the North Carolina Medical Board in North Carolina before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where Charles Kuzma, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Charles Kuzma, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$17.1K
Largest payer
AstraZeneca Pharmaceuticals LP
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Above average
26% brand-name claims vs 74% generic, on 1,178 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,662
- Total Day Supply
- 44,714
- Brand vs Generic
- 26% brand / 74% generic
- Brand Drug Cost
- $4.4M
- Generic Drug Cost
- $738K
- Opioid Claims
- 36 (3.1% rate)
- Antibiotic Claims
- 16
Patient Demographics
- Average Patient Age
- 72.9 years
- Avg HCC Risk Score
- 2.01
- Gender Split
- 68% female / 32% male
- Age Distribution
- <65: 26, 65-74: 103, 75-84: 72, 85+: 19
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Charles Kuzma, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Letrozole
Letrozole
108 claims
- Revlimid
Revlimid
86 claims
- Tamoxifen Citrate
Tamoxifen Citrate
65 claims
- Anastrozole
Anastrozole
56 claims
- Gabapentin
Gabapentin
52 claims
- Ondansetron Hcl
Ondansetron Hcl
48 claims
- Levothyroxine Sodium 40
Levothyroxine Sodium
40 claims
- Lenalidomide 39
Lenalidomide
39 claims
| Drug | Claims |
|---|---|
| Letrozole | 108 |
| Revlimid Lenalidomide | 86 |
| Tamoxifen Citrate | 65 |
| Anastrozole | 56 |
| Gabapentin | 52 |
| Ondansetron Hcl | 48 |
| Levothyroxine Sodium | 40 |
| Lenalidomide | 39 |
| Dexamethasone | 38 |
| Prochlorperazine Maleate | 36 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Charles Kuzma, M.D. fits within the Hematology & Oncology Physician landscape nationally.
Charles Kuzma, M.D.'s 1,178 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in North Carolina
Other clinicians with the same primary specialty enrolled in North Carolina, drawn from the same CMS NPPES roster as Kuzma.
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the North Carolina medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Hematology & Oncology Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore North Carolina
Frequently Asked Questions
What is Charles Kuzma, M.D.'s specialty? ▼
How much does Charles Kuzma, M.D. prescribe under Medicare Part D? ▼
What is Charles Kuzma, M.D.'s Medicare quality score? ▼
Where is Charles Kuzma, M.D. located? ▼
What is Charles Kuzma, M.D.'s NPI number? ▼
Does Charles Kuzma, M.D. prescribe more brand-name or generic drugs? ▼
Does Charles Kuzma, M.D. prescribe opioids? ▼
How many Hematology & Oncology Physician providers are there in the US? ▼
What drugs does Charles Kuzma, M.D. prescribe most often? ▼
Does Charles Kuzma, M.D. accept Medicare? ▼
How can I verify Charles Kuzma, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology